Trial Profile
Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors AbbVie
- 25 May 2018 Status changed from active, no longer recruiting to completed.
- 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2017 Planned End Date changed from 1 Sep 2017 to 31 Mar 2018.